drugset

drugset / Trial / NCT00685945

Renin-Angiotensin Aldosterone System and Fibrinolysis Interaction in Humans-Specific Aim 3

NCT00685945 ↗

Completed 24 enrolled Vanderbilt University National Center for Research Resources (NCRR) · collab National Heart, Lung, and Blood Institute (NHLBI) · collab National Institutes of Health (NIH) · collab

RandomizedCrossoverSingle-blindHealth-services research

Summary

The purpose of the study is to determine if giving isosorbide,a drug that is used to treat chest pain, affects blood vessel release of an anti-clotting factor.

Timeline

Start: 2007-12
Primary completion: 2009-01
Completion: 2009-01

Publications

Results Pretorius M, Brown NJ. Endogenous nitric oxide contributes to bradykinin-stimulated glucose uptake but attenuates vascular tissue-type plasminogen activator release. J Pharmacol Exp Ther. 2010 Jan;332(1):291-7. doi: 10.1124/jpet.109.160168. Epub 2009 Oct 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bradykinin	Protein / enzyme biologic	50 ng	Other
Subject	Bradykinin	Protein / enzyme biologic	100 ng	Other
Subject	Bradykinin	Protein / enzyme biologic	200 ng	Other
Subject	Isosorbide Dinitrate	Other / unclassified	5 mg	—
Subject	L-NMMA	Unknown	0.012 mmol	Other
Subject	Sildenafil	Unknown	50 mg	—

Indications